Microsoft's AI Growth Impresses, but Capacity and Margin Hurdles Persist
Read source articleWhat happened
Microsoft posted robust Q3 results with 18% revenue growth and 40% Azure growth, while AI revenue surged 123% YoY, fueling bullish analyst projections of $513 to $550 per share. However, the DeepValue Master Report maintains a WAIT rating, cautioning that Azure remains capacity-constrained through FY26 and cloud gross margin is under pressure from heavy AI capex and rising depreciation. The article's optimism hinges on sustained Copilot adoption and demand-led capex, but the master report underscores that margin stabilization and a demonstrable easing of capacity limits are not yet proven. The 45% of commercial RPO tied to OpenAI adds concentration risk, and the amended OpenAI contract allows multi-cloud if Microsoft falters on capacity delivery. Until these proofs materialize, the stock at 26.7x P/E offers limited margin of safety despite its strong operational momentum.
Implication
Over the next 12 months, the stock's direction depends on two key proofs: Azure growth persisting above 35% constant-currency as capacity constraints fade by June 2026, and Microsoft Cloud gross margin stabilizing around 65% despite elevated capex. If these are met, the bull case to $520 is credible; if not, multiples could compress toward the $400 attractive entry level. The article's $513 target is achievable only if the capacity ramp delivers, but the master report's bias suggests patience is warranted until the next quarterly filings confirm the trend.
Thesis delta
The Seeking Alpha article introduces a more aggressive near-term upside scenario based on Q3 momentum and AI growth, but does not resolve the master report's central concerns: capacity gating and margin dilution. The thesis shifts from 'wait for proofs' to 'acknowledge strong execution but maintain discipline until constraints lift and margins steady.' The fundamental risk-reward remains unchanged: the stock is a show-me story, and the article does not provide new evidence that alters the wait-and-see stance.
Confidence
Medium